ArticleGene therapy2016
Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility.
Article in Gene therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models.Molecular therapy oncolytics · 2022Article
- Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers.Cancers · 2022Review
- Progress of oncolytic virotherapy for neuroblastoma.Frontiers in pediatrics · 2022Review
- USP18 and USP20 restrict oHSV-1 replication in resistant human oral squamous carcinoma cell line SCC9 and affect the viability of SCC9 cells.Molecular therapy oncolytics · 2021Article
- High accumulation of Mx2 renders limited multiplication of oncolytic herpes simplex virus-1 in human tumor cells.Scientific reports · 2021Article
- Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma.iScience · 2021Article
- Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Engineered stem cells targeting multiple cell surface receptors in tumors.Stem cells (Dayton, Ohio) · 2020Review
- Immunotherapeutic Challenges for Pediatric Cancers.Molecular therapy oncolytics · 2019Review
- Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.BMC cancer · 2019Article
- First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Review
- Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.Journal of virology · 2019Article
- Pediatric Cancer Immunotherapy: Opportunities and Challenges.Paediatric drugs · 2018Review
- Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.Scientific reports · 2018Article
- HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.Viruses · 2018Article
- Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice.Cancer science · 2018Article
- Experimental Dissection of the Lytic Replication Cycles of Herpes Simplex VirusesFrontiers in microbiology · 2018Review
- Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.Molecular therapy oncolytics · 2017Article
- Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based VectorsIranian biomedical journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
Abstract
Although most high-risk neuroblastomas are responsive to chemotherapy, relapse is common and long-term survival is < 40%, underscoring the need for more effective treatments. We evaluated the responsiveness of 12 neuroblastoma cell lines to the Δγ134.5 attenuated oncolytic herpes simplex virus (oHSV), Seprehvir (HSV1716), which is currently used in pediatric phase I trials. We found that entry of Seprehvir in neuroblastoma cells is independent of the expression of nectin-1 and the sum of all four known major HSV entry receptors. We observed varying levels of sensitivity and permissivity to Seprehvir, suggesting that the cellular anti-viral response, not virus entry, is the key determinant of efficacy with this virus. In vivo, we found significant anti-tumor efficacy following Seprehvir treatment, which ranged from 6/10 complete responses in the CHP-134 model to a mild prolonged median survival in the SK-N-AS model. Taken together, these data suggest that anti-tumor efficacy cannot be solely predicted based on in vitro response. Whether or not this discordance holds true for other viruses or tumor types is unknown. Our results also suggest that profiling the expression of known viral entry receptors on neuroblastoma cells may not be entirely predictive of their susceptibility to Seprehvir therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.